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Bat IFITM3 restriction depends on S-palmitoylation and a
polymorphic site within the CD225 domain
Camilla TO Benfield1 , Farrell MacKenzie2, Markus Ritzefeld3, Michela Mazzon2 , Stuart Weston2, Edward Tate3 ,
Boon Han Teo1, Sarah E Smith5, Paul Kellam4,5 , Edward C Holmes6, Mark Marsh2
Host interferon-induced transmembrane proteins (IFITMs) are
broad-spectrum antiviral restriction factors. Of these, IFITM3
potently inhibits viruses that enter cells through acidic endo-
somes, many of which are zoonotic and emerging viruses with
bats (order Chiroptera) as their natural hosts. We previously
demonstrated that microbat IFITM3 is antiviral. Here, we show
that bat IFITMs are characterized by strong adaptive evolution
and identify a highly variable and functionally important
site—codon 70—within the conserved CD225 domain of IFITMs.
Mutation of this residue in microbat IFITM3 impairs restriction of
representatives of four different virus families that enter cells via
endosomes. This mutant shows altered subcellular localization and
reduced S-palmitoylation, a phenotype copied by mutation of
conserved cysteine residues in microbat IFITM3. Furthermore, we
show that microbat IFITM3 is S-palmitoylated on cysteine residues
C71, C72, and C105, mutation of each cysteine individually impairs
virus restriction, and a triple C71A-C72A-C105A mutant loses all
restriction activity, concomitant with subcellular re-localization of
microbat IFITM3 to Golgi-associated sites. Thus, we propose that
S-palmitoylation is critical for Chiropteran IFITM3 function and
identify a key molecular determinant of IFITM3 S-palmitoylation.
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Introduction
Interferon-induced transmembrane proteins (IFITMs) are antiviral
factors that act uniquely and early in viral replication cycles to restrict
the entry of a diverse range of primarily enveloped viruses into cells
(1). Humans possess three IFN-inducible IFITM genes—IFITM1, IFITM2,
and IFITM3—encoding proteins with antiviral functions and two IFITM
family members that lack antiviral function—IFITM5 and IFITM10. Mice
have orthologs of all these IFITMs as well as two additional genes,
Ifitm6 and Ifitm7. Phylogenetic analysis of vertebrate IFITMs indicates
that IFITM1, IFITM2, and IFITM3 group with murine ifitm6 and ifitm7 in a
clade of immunity-related IFITMs (IR-IFITMs), with IFITM5 and IFITM10
falling as separate lineages (2). IFITMs belong to the CD225/pfam04505
or “dispanin” protein superfamily (http://pfam.xfam.org/family/
PF04505) (3) that contains more than 2,000 members, including
both prokaryotic and eukaryotic proteins, all of which encode a
conserved CD225 protein domain.
As their name suggests, IFITMs are membrane proteins, allowing
them to police the cell surface and endocytic membranes that
virusesmust cross to invade cells. Studies of IFITM topology suggest
a type II transmembrane configuration with a cytosolic N terminus,
cytosolic conserved intracellular loop (CIL) domain, transmembrane
domain, and extracellular (or intraluminal) C terminus (4, 5), al-
though there is evidence that other IFITM topologies exist (6, 7, 8).
The results of spectroscopic topological studies agree with the type
II transmembrane configuration, as do bioinformatic predictions of
IFITM3 secondary structure that reveal three alpha helices, with the
C-terminal helix forming a single transmembrane domain (9, 10).
The CD225 domain is highly conserved among IFITMs and comprises
an intramembrane domain (IMD) and CIL domain. The hydrophobic
IMD contains a 10-residue amphipathic helix (amino acid residues
59–68 of human IFITM3) that is required for the antiviral activity of
both IFITM3 and IFITM1 (9). The subcellular localization of IFITMs is a
key determinant of their antiviral profile. When expressed singly,
IFITM3 and IFITM2 preferentially localize to early and late endo-
somes and lysosomes, restricting viruses that enter via these
endolysosomal compartments. In contrast, IFITM1 primarily local-
izes at the cell surface and can restrict viruses that enter through
the plasma membrane (11, 12, 13, 14). Indeed, mutants of IFITM3 that
lack an N-terminal endocytic sorting motif 20YEML23 localize to the
plasma membrane and lose their ability to inhibit influenza A virus
(IAV), alphavirus, and coronavirus infection by endosomal routes
(14, 15, 16, 17, 18).
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Studies focusing on IFITM3 restriction of IAV and Semliki Forest
virus (SFV) indicate that virus internalization is unaffected by IFITM3
expression and, for SFV at least, the viral envelope glycoprotein
undergoes low pH-induced conformational changes (14). However,
for both viruses, the viral core components are not delivered to the
cytoplasm, suggesting that membrane fusion fails. Experiments
with IAV indicate that hemifusion (i.e., lipid-mixing between viral
and cellular membranes) can occur in the presence of IFITM3, but
the subsequent formation of a fusion pore is inhibited (13, 19). Recent
work has shown that IFITM3-positive vesicles fuse with incoming
virus-bearing vesicles before hemifusion and that IFITM3 enhances
the rate of virus trafficking to lysosomes (20). The co-localization of
viral cargo with IFITM3-positive endosomes is specific to restricted
viruses, suggesting that IFITM-insensitive viruses such as Lassa
virus enter via different endosomal compartments and thereby
escape IFITM engagement and restriction (13, 20). Further examples
of virus-specific IFITM action include the ability of murine IFITM6 to
restrict filoviruses, but not IAV (21), and amino acids within the
IFITM3 CIL domain that are preferentially needed for IAV but not
dengue virus restriction (22). Other post-entry mechanisms for
IFITM3 restriction have also been proposed (23, 24, 25).
IFITMs are heavily regulated by posttranslational modifications
(PTMs). One major modification is S-palmitoylation, a reversible 16-
carbon lipid PTM that increases protein hydrophobicity and in-
fluences the behavior of proteins in membrane environments (26).
For human and murine IFITM3, S-palmitoylation can occur on
cysteine residues 71, 72, and 105 and enhances IFITM3 antiviral
activity (27, 28). Recent live-cell imaging showed that abrogating C72
palmitoylation slowed IFITM3 trafficking to membrane compart-
ments containing IAV particles (20). Multiple zinc finger DHHC
(Asp-His-His-Cys) domain–containing palmitoyltransferases (ZDHHCs)
can palmitoylate IFITM3 with marked functional redundancy, al-
though ZDHHC20 may be particularly important (29). For human
IFITM3, C72 is also the dominant site for acylation (30). Three other
PTMs have also been reported, all of which negatively regulate
IFITM3 antiviral activity: ubiquitination on one or more of four lysine
residues (27), methylation on K88 (31), and phosphorylation on Y20
(15, 16). IFITM3 also forms homo- and hetero-oligomers. Although
these are thought to require amino acids F75 and F78 (22), a recent
study reported that these residues are required for antiviral activity
but not for IFITM3-IFITM3 interactions (32). In tissue culture systems
at least, IFITM3, IFITM2, and IFITM1 restrict viruses in a cooperative
manner, with the extent of cooperativity and redundancy between
IFITMs varying for different viruses (20, 22). However, the biochemical
mechanisms and molecular determinants by which IFITM proteins
restrict virus infection are still far from clear.
In mice and humans, there is evidence that IFITM3 influences
host antiviral resistance. Ifitm3 knockout mice show enhanced
morbidity after infection with IAV, alphaviruses, and flaviviruses (33,
34, 35, 36), and in humans, single nucleotide polymorphisms in
IFITM3, which may act by altering IFITM3 expression or subcellular
distribution, have been associated with an increase in morbidity in
IAV andHIV-1 infections (recently reviewed by references 37 and 38).
Antiviral function has also been reported for IFITMs from diverse
mammalian and avian species (39, 40, 41, 42, 43, 44), although little is
known about the role of IFITMs in antiviral defense in these species
and in shaping host range. Phylogenetic studies have shown that
the IFITM gene family is evolutionarily conserved and characterized
by gene duplication, copy number variation, and the presence of
pseudogenes (2, 45). Whereas humans possess a single IFITM3 gene,
a remarkable multiplicity of IFITM3-like genes exists in the genomes
of some other primates; for example, there are 25 IFITM3-like
variants in the marmoset and eight in the African green monkey
(2, 46). Interestingly, several of these variants contain N-terminal
polymorphisms which, when inserted into human IFITM3, prevent
ubiquitination and endocytosis; however, the function of these
duplicated IFITM3-like genes has not been tested (46).
The antiviral responses of bats (mammalian order Chiroptera)
are of particular interest because these animals have been in-
creasingly recognized as reservoir hosts from which numerous
viruses have ultimately emerged, with severe pathogenic and
socioeconomic consequences in humans and livestock. Indeed, a
recent analysis showed that bats host a significantly higher
proportion of zoonotic viruses than other mammalian orders
(47). Moreover, Chiroptera are the only mammalian order that
harbor significantly more zoonotic viruses than predicted from
reporting effort and host traits such as geographic range and
mammal sympatry. It is possible that this propensity to be
reservoirs for a large number of viruses, many of which may
remain asymptomatic, in part reflects aspects of bat immunology
(48, 49, 50, 51, 52). Hence, the study of Chiropteran antiviral ef-
fectors, such as IFITMs, can potentially reveal mechanisms of
viral tolerance as well as the evolutionary signatures of virus–
host co-evolution. We previously showed that microbat IFITM3
retains sequence motifs for endocytosis and PTM, traffics to the
plasma membrane before endocytic uptake, co-localizes with
endosomal markers, and at normal expression levels in primary
microbat cells, inhibits infection by pH-dependent enveloped
viruses (39).
Here, we performed evolutionary analyses of mammalian IFITMs,
including those identified from bats, to shed light on IFITM function
and the nature of past selection pressures, and to identify key
amino acids for experimental studies of IFITM function.
Results
Phylogenetic analysis of Chiropteran IFITM genes
Viral restriction activity is conserved in microbat IFITM3 (39).
However, Chiropteran IFITMs have not been included in previous
phylogenetic analyses, although bats comprise ~20% of all mam-
malian species. Accordingly, we first analyzed the phylogenetic
relationships of IR-IFITM gene sequences from 31 eutherian
mammal species, including 13 species of bat. The genes analyzed
were identified either via translated BLAST (tBLAST) or from our
cDNA analyses (rapid amplification of cDNA ends [RACE] on cells
from Myotis myotis, Eptesicus serotinus, and Sus scrofa and pro-
teomics informed by transcriptomics (53) for Pteropus alecto). The
resulting phylogeny revealed relatively high levels of sequence
divergence (nucleotide substitutions per site) between the IFITM
genes (Fig 1). Notably, Chiropteran IFITMs formed a monophyletic
group separated from other taxa by a relatively long branch.
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Figure 1. Evolutionary history of mammalian IFITM genes.
The phylogeny represents a maximum likelihood analysis of 148 IFITM genes, with mammalian orders and the Laurasiatheria clade indicated. The Chiropteran IFITM
genes are shown in red. The tree was rooted according to the overall mammalian phylogeny (54). Nodes marked with * have both SH-support value > 0.9 and bootstrap
value > 70%. Scale bar shows the number of nucleotide substitutions/site.
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Adaptive evolution on the branch leading to the Chiropteran
IFITMs
The IFITM gene family is notable for gene duplications, variation
in copy number, and the presence of pseudogenes (2, 55), and
our previous tBLAST searches identified multiple IFITM-like
genes for many species. In most cases, there are little data to
differentiate functional from nonfunctional IFITM-like genes.
Therefore, to assess possible selection pressures, we performed
phylogenetic analysis on a selection of mammalian IR-IFITM
genes for which there is evidence of function (Table S1): this
data set comprises 31 IFITMs from 17 species, including eight
Chiropteran species (Fig 2A). The selection pressures acting on
these IFITM genes were assessed through analyses of the
numbers of non-synonymous (dN) to synonymous (dS) nucleo-
tide substitutions per site, with dN > dS indicative of positive
selection (i.e., adaptive evolution), performed using the adaptive
Branch-Site Random Effects Likelihood method (56) that is able
to determine selection pressures acting on specific branches of
the input phylogeny. This analysis revealed that 6.8% of the
codons in the sequence alignment were strongly positively
selected on the branch leading to all Chiropteran IFITMs, with a
dN > dS of infinity (Likelihood ratio test = 14.95; P = 0.002).
Codon 70 is highly diverse among mammalian IFITMs
To visualize amino acid diversity, a logo diagram was constructed
for the alignment of 31 “functional” IFITMs. This revealed notable
amino acid diversity at codon 70, located within the otherwise
highly conserved CD225 domain and directly upstream of the
double cysteine motif C71/C72 (Fig 2B). The amino acids at codon 70
for the 31 functional mammalian IFITMs, as well the likely ancestral
codons at this site at key nodes in the phylogeny inferred using a
parsimony procedure, are indicated on Fig 2A. The human IFITM3,
IFITM2, and IFITM1 proteins each encode a distinct amino acid at
codon 70 (P, T, and W, respectively). A further three amino acids
occur in IFITM proteins with confirmed antiviral activity: F (in mouse
IFITM3 and IFITM1), A (in mouse IFITM2), and G (in mouse IFITM6; not
used in the phylogenetic analysis). Assessing novel IFITM3 se-
quences, we obtained using RACE and RT-PCR for four species of
microbat also highlighted codon 70 as the only non-conserved
residue within the CD225 domain of microbat IFITM3, and it was
notable that twomicrobat species encode valine (V) at this position
(Fig 2C).
We next performed a site-specific selection analysis using
the phylogeny of the 31 functional IFITMs shown in Fig 2A. Using the
single-likelihood ancestor counting method, codon 121, within the
C-terminal IFITM domain, was the only site identified as under
significant positive selection (P < 0.1; mean dN-dS value of 2.64).
Although there was no statistically significant evidence for positive
selection on codon 70 (P = 0.192), it had the second highest dN-dS
value of any site (1.91), with 14 non-synonymous nucleotide changes
(compared with 13.5 at codon 121) and only two synonymous
changes across the phylogeny. Similar results (i.e., close to sig-
nificant positive selection) were obtained using the fast un-
constrained Bayesian approximation method.
Codon 70 affects antiviral restriction by microbat IFITM3
To assess the functional effects of variation at codon 70, polyclonal
stable A549 cells were made expressing C-terminally HA-tagged
wild-type (wt) human IFITM3 (i.e., huIFITM3 P70) and human IFITM3
encoding each of the other six amino acids that occur naturally in
mammals at position 70 (i.e., A, T, G, W, F, and V). In addition, we
made C-terminally HA-taggedwtmicrobatM.myotis IFITM3 (mbIFITM3)
and a mbIFITM3 P70W mutant: W is a possible ancestral codon for
the Laurasiatherian and primate IFITM clades (Fig 2A) and occurs in
functional IFITMs such as pig IFITM3 and human IFITM1, but not in
the bat IFITMs sequenced to date.
Themutant IFITM3 proteins were tested for their ability to restrict
cell entry by Zika virus (ZIKV), SFV, and IAV (Fig 3). Flow cytometry
was used to determine the proportion of infected cells after single
cycle infection, and a representative experiment of three inde-
pendent experiments is shown (Fig 3A–C). Each of the huIFITM3
codon 70 mutants restricted ZIKV infectivity with similar potency as
wt huIFITM3 and wt mbIFITM3 (all <4% infection at an MOI of 10
and <1% infection at an MOI of 1). In contrast, mbIFITM3 P70W was
significantly less restrictive than wt (35% ZIKV infection at an MOI of
10 and 7% at an MOI of 1) (Fig 3A). Similarly, small variations in
infectivity of both SFV (Fig 3B) and IAV (Fig 3C) were apparent for the
huIFITM3 codon 70 mutants, whereas infectivity of both viruses was
markedly higher in cells expressing mbIFITM3 P70W compared with
wt mbIFITM3. Expression levels of wt mbIFITM3 and mbIFITM3 P70W
were comparable when analyzed by Western blotting (Figs 3A and B,
S1A, and B) and flow cytometry (Fig S1C and D). Thus, differences in
expression do not account for the different antiviral activities of
these proteins. Using multi-cycle IAV infection, we investigated
the impact on infectious yields and found that cells expressing
mbIFITM3 P70W gave eightfold greater IAV titres than cells expressing
wt mbIFITM3 (Fig 3D). Overall, the P70W substitution in mbIFITM3
significantly reduces restriction of representatives of three different
virus families that enter cells via pH-dependent fusion from
endosomes.
P70W alters the subcellular localization of mbIFITM3
To assess the impact of P70 mutations on the subcellular locali-
zation of huIFITM3 and mbIFITM3, confocal immunofluorescence
imaging was performed on A549 cells stably expressing either wt or
P70W mutants of C-terminally HA-tagged huIFITM3 and mbIFITM3
(Fig 4). In fixed and permeabilized cells, wt huIFITM3 and mbIFITM3
had a punctate intracellular distribution, as described previously
(5, 39), and huIFITM3 P70W showed a similar localization (Fig 4). In
contrast, mbIFITM3 P70W showed a different distribution, with
prominent perinuclear Golgi-like labelling (Fig 4A, permeabilized).
When cells were labelled in the absence of detergent (Fig 4A, intact),
some wt huIFITM3 was detected at the cell surface, as reported
previously (5), and this was similar for huIFITM3 P70W. The strong
cell surface labelling seen for wt mbIFITM3 was much reduced for
mbIFITM3 P70W (Fig 4A, intact), suggesting reduced trafficking to the
plasmamembrane. To examine IFITM3 trafficking to the cell surface,
the cells were incubated inmedium containing anti-HAmAb at 37°C
for 60 min before fixation with or without permeabilization (Fig 4B)
to reveal internalised or cell surface anti-HA antibodies, respectively.
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Figure 2. Lineage-specific adaptive evolution in Chiropteran IFITMs and codon 70 diversity.
(A) Phylogeny of 31 IFITM genes with evidence of function that was used to analyze selection pressures. A total of 384 well-aligned nucleotides was used for maximum
likelihood phylogenetic analysis. The clade of Chiropteran IFITMs, identified as under strong positive selection, is indicated in red. Nodes marked with * have both SH-
support value > 0.9 and bootstrap value > 70%. Scale bar shows the number of nucleotide substitutions/site, and the tree was rooted according to the overall mammalian
phylogeny (54). The amino acid residues at codon 70 in mammalian IFITMs, as well as their likely ancestral states inferred using a parsimony procedure, are also shown.
(B) Sequence logo for IFITM gene alignment used for Fig 2A with codon 70 highlighted. (C) Amino acid alignment of IFITM3 from four different microbat species. IFITM3
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In cells expressing huIFITM3s, similar intracellular punctate labelling
was observed on permeabilized cells, suggesting that equivalent
trafficking to the cell surface and subsequent endocytosis occurred
for both wt and huIFITM3 P70W. Consistent with this, similar levels of
cell surface labelling were seen for both proteins on intact cells.
Significant intracellular labelling (permeabilized cells) and cell
surface labelling (intact cells) was seen on cells expressing wt
mbIFITM3, but very little internal or cell surface staining was seen for
cells expressing mbIFITM3 P70W. Together, these data indicate that
the P70W mutation in mbIFITM3 significantly reduces trafficking of
the protein to the cell surface and, as a consequence, there is little
subsequent endocytic uptake of the protein into endosomal
compartments.
As our initial observations suggested mbIFITM3 P70W may be
preferentially associated with Golgi compartments (Fig 4A), we co-
labelled fixed and permeabilized cells with anti-HA mAb (to detect
theHA-tagged IFITM3 protein) andmarkers of intracellular organelles.
Clear overlap was seen for the perinuclear concentrations of mbI-
FITM3 P70W with the cis Golgi marker Giantin (Fig 4C) and with the
trans Golgi network marker TGN46 (Fig S2A), whereas the huIFITM3
proteins andwtmbIFITM3 showed significantly less overlap. Together,
these data suggest that mbIFITM3 P70W showed increased associ-
ation with the Golgi apparatus and reduced trafficking to the cell
surface compared with the wt mbIFITM3 protein and the huIFITM3
proteins. Moreover, huIFITM3 P70W did not show any obvious alter-
ation in its trafficking properties and behaved similarly to the wt
protein. These properties correlated with the reduced viral restriction
observed for mbIFITM3 P70W (Fig 3).
P70W reduces S-palmitoylation of mbIFITM3
IFITM3 codon 70 is located directly adjacent to C71 and C72 (Fig 2C),
which are conserved and S-palmitoylated in human and murine
IFITM3. Therefore, we assessed S-palmitoylation levels of wt and
cDNA sequences were identified via RACE and RT-PCR (M. myotis previously (39)). Translated sequences were aligned using Clustal Omega. Text colour of amino acid
residues denotes their physiochemical properties: blue, acidic; red, small and hydrophobic; magenta, basic; green, hydroxyl, sulfhydryl, amine, and glycine. An asterisk
indicates identical amino acid residues, “:” indicates residues with strongly similar properties, and “.” indicates residues with weakly similar properties. Codon 70 is
highlighted in yellow. IFITM3 domains IMD and CIL, together comprising the CD225 domain, are shown (according to reference 22).
Figure 3. Antiviral restriction by codon 70 mutants of
human and microbat IFITM3.
(A, B) A549 cells expressing the indicated IFITM3
proteins (or untransduced [untrans.] controls) were
infected at an MOI of 10 or 1 (alongside uninfected
controls) with either ZIKV for 28 h (A) or SFV_Zs-Green
for 8 h (B). For (A), % infection was determined by flow
cytometry using an anti-flavivirus primary antibody
and AF 488–conjugated secondary antibody (%
infection = % AF 488 positive cells). For (B), % infection
was determined by flow cytometry as % of Zs-Green
positive cells. (A, B) Data are from a representative
experiment (n = 3) performed in triplicate (duplicate for
uninfected controls) with each bar showing themean
± SEM. Beneath each graph is a corresponding Western
blot showing IFITM3 expression for that assay. IFITM3
proteins were detected with an anti-HA antibody.
Calreticulin was used as a loading control. (C) A549
cells expressing the indicated IFITM3 proteins, or
untransduced (untrans.) A549 cells, were infected
with IAV at an MOI of 10. After 6 h, % infection (i.e., % NP
positive cells) was determined using flow cytometry
using FITC-conjugated anti-NP antibody. (D) Mean ±
SEM of triplicate infections is shown (**P < 0.01, t test)
(D) A549 cells expressing wt mbIFITM3 or mbIFITM3
P70W, or untransduced (untrans.) A549 cells, were
infected with IAV at an MOI of 0.01 and 48 h later
supernatants were harvested and the viral yields
titrated onMDCK cells by plaque assay. Mean ± SEM of
triplicate infections each titrated in duplicate is shown
(*P < 0.05, t test).
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codon 70 mutants of hu and mbIFITM3 using a protocol based on
the acyl-PEG exchange (APE) method developed by Percher et al
(30, 57) in which we used maleimide-functionalised biotin to se-
lectively substitute S-acylations (Fig S3A). Treatment of these
samples with streptavidin induces a mass shift of the biotinylated
proteins detectable by Western blotting (Fig S3B). Thereby, the
intensity of the shifted band correlates with the amount of
S-acylated protein. Whole cell lysates from IFITM3-expressing
stable A549 cells were subject to the acyl exchange workflow (Fig
S3A) and streptavidin treatment. After SDS–PAGE and anti-HA
Western blotting, a band was observed that migrated at ~75 kDa
(Fig 5B), which is consistent with the expected size of one strep-
tavidin (Molecular Weight [MW] ~60 kDa) bound to one IFITM3-HA
(MW ~15 kDa). Hence, this band represents S-palmitoylated IFITM3
present in the A549 cell lysates. The high MW band was dependent
both on the presence of streptavidin and the addition of NH2OH (Fig
S3B). Furthermore, titrating streptavidin showed that the amount
used in this study was non-limiting (Fig S3B). Blurred bands at
higher MW above the predominant 75 kDa band (Figs 5B and S3B)
likely represent binding of additional streptavidin molecules to the
second and/or third cysteine residue. Therefore, the entire area at
and above the 75 kDa band was used for the densitometric analysis.
Triplicate lysates for each cell line were subjected to acyl exchange,
independent SDS–PAGE, and anti-HA blotting. Densitometry was
then performed in Image J to determine the proportion of each
IFITM3 protein that was S-palmitoylated, that is, (HA signal ≥ 75
kDa)/(total HA signal in lane) (Fig 5A). The mbIFITM3 proteins
showed a lower degree of S-palmitoylation compared with huI-
FITM3. Among the codon 70 mutants, the most marked difference
was significantly reduced S-palmitoylation for mbIFITM3 P70W
compared with wt mbIFITM3 (Fig 5A).
Microbat IFITM3 is S-palmitoylated on C71, C72, and C105
S-palmitoylation of IFITMs has only previously been studied for
human and mouse proteins. To investigate S-palmitoylation in
mbIFITM3, cysteine-to-alanine substitutions weremade at conserved
cysteine residues (C71, C72, and C105). A549 cells stably expressing
single mutants C71A, C72A, and C105A, the double C71A-C72A mutant
and the triple C71A-C72A-C105Amutant were generated. Twomethods
were used to assess S-palmitoylation: (i) the acyl exchange gel shift
method described above (Figs 5, and 6A and B), and (ii) visualisation
of palmitoylated proteins by in-gel fluorescence (Fig 6C and D). For
this, the cells were metabolically labelled with a “clickable” alkyne
Figure 4. Subcellular localization of IFITM3 proteins.
Immunofluorescence of A549 cells stably expressing HA-tagged wt huIFITM3, huIFITM3 P70W, wtmbIFITM3, ormbIFITM3 P70W (or untransduced A549 cells). (A) Cells were
fixed and stained for HA with permeabilization (permeabilized) or without (intact). (B) Live cells were incubated with anti-HA for 60 min at 37°C then fixed and
subsequently stained with a secondary antibody with permeabilization (permeabilized) or without (intact). (C) Cells were fixed, permeabilized, and stained for HA and the
cis Golgi marker Giantin. Nuclei were labelled with Hoechst and images taken on a confocal microscope. Scale bars represent 20 μm.
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palmitate analogue followed by further modification of the pal-
mitoylated proteins via copper-catalyzed azide–alkyne cycloaddi-
tion reaction (i.e., “click chemistry”) using a TAMRA-labelled capture
reagent. The described metabolic labelling approach has been
extensively used to successfully quantify a variety of PTMs (58, 59,
60). Comparing the two orthogonal methods (acyl exchange and
metabolic labelling) used in this study reveals that both approaches
have different informational value. The acyl exchange method only
enables the quantification of the total amount of palmitoylated
IFITM3. Because of themulti-valency of the streptavidin, multiple PTMs
might still result in a 1:1 ratio of the IFITM3:streptavidin complex if the
corresponding sites are in close vicinity. However, because of the
significant shift of the IFITM3:streptavidin complex, palmitoylated and
non-palmitoylated IFITM3 can be quantified in the same blot, thereby
facilitating an internal normalization. The metabolic labelling ap-
proach enables the quantification of all palmitoylation sites, as
each PTM contributes directly to the total TAMRA fluorescence
intensity. However, for quantitative analysis, the TAMRA fluores-
cence must be normalized to the HA blot signal to account for
variation in IFITM3-HA expression (Fig 6C) leading to larger error
bars. The different informational value becomes obvious in the
case of wt huIFITM3 and wt mbIFITM3. Although the TAMRA fluo-
rescence for wt huIFITM3 was greater than for wt mbIFITM3 and
huIFITM3 P70W (Fig 6C), the acyl exchange result did not show a
significant difference in the proportion of palmitoylated protein in
either case (Fig 6A). Hence, the total amount of palmitoylated IFITM3
is equivalent in all three cases; however, the number of palmi-
toylations per protein differs.
Importantly, the results of both methods for the different cys-
teinemutants of mbIFITM3 showed that the single cysteinemutants
(C71A, C72A, and C105A) have reduced palmitoylation compared with
wt mbIFITM3, with a greater reduction for C72A than C71A. A double
C71A–C72A mutant still showed some acylation, indicating that C105
can be acylated, whereas the triple mutant abrogated palmitoy-
lation (Fig 6A–D). In summary, our data show that, as with human
and mouse IFITM3, microbat IFITM3 can be S-palmitoylated on each
of the three cysteine residues, with C72 being the preferred site.
Furthermore, mbIFITM3 P70W showed a comparable reduction in
S-palmitoylation to the single cysteine mutants of mbIFITM3.
Palmitoylation-defective cysteine mutants of mbIFITM3
phenocopy the P70W mutation
We next studied the ability of the mbIFITM3 S-palmitoylation–
defective cysteine mutants to restrict viral entry. The infectivity of
ZIKV, SFV, and virus pseudotypes expressing the envelope proteins
Figure 5. S-palmitoylation levels of codon 70 IFITM3
mutants.
A549 cells stably expressing the indicated HA-tagged
hu and mbIFITM3 proteins were lysed and subjected to
acyl–biotin exchange, in triplicate, for each IFITM3-
expressing cell line. Streptavidin was then added to
enable visualisation of biotin-modified (i.e.,
S-palmitoylated) IFITM3 by gel shift after SDS–PAGE
(4 μg total protein loaded) and anti-HA Western blotting.
(A) Proportion of total IFITM3 protein palmitoylated,
given by densitometric quantification (Image J) of
(shifted HA signal)/(total HA signal). Mean ± SEM of
triplicate lysates each run on separate gels and blotted
independently is shown (**P < 0.01, *P < 0.05, t test).
(B) Representative anti-HA and anti-actin blot (same
membrane). Arrows indicate the non-palmitoylated
portion of IFITM3 running at ~15 kDa and the
S-palmitoylated fraction which is shifted because of
bound streptavidin.
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of the lyssaviruses West Caucasian Bat virus (WCBV) and Lagos Bat
virus (LBV) was tested in cells expressing either wt mbIFITM3,
mbIFITM3 P70W, or the cysteine mutants of mbIFITM3 (Fig 7). All
cysteine mutants showed impaired restriction relative to wt mbI-
FITM3, with a predominant pattern of greatest restriction by C71A >
C105A > P70W > C72A (Fig 7A–D). The double (C71A-C72A) and triple
(C71A-C72A-C105A)mutants showed no restriction relative to control
cells (Fig 7A–D). This is consistent with S-palmitoylation being greatest
for C71A and abrogated for the triple cysteinemutant (Fig 6), indicating
that palmitoylation positively regulates the antiviral activity of
mbIFITM3. For comparison, wt huIFITM3 and huIFITM3 P70W were
also tested in lyssavirus entry assays. As seen earlier for ZIKV, SFV,
and IAV, the huIFITM3 P70W protein restricted lyssavirus entry as
potently as wt huIFITM3 (Fig 7C and D).
Immunofluorescence analysis was performed on stable A549
cells expressing the HA-tagged versions of the different mbIFITM3
cysteine mutants. All single Cys mutants, as well as the double and
triple mutants showed preferential perinuclear localization and a
reduction in the more widely distributed punctate localization
characteristic of wt mbIFITM3 (Fig 8A, permeabilized). The intra-
cellular redistribution correlated with reduced exposure of IFITM3
at the cell surface (Fig 8A, intact). This was most marked for the
double and triple cysteine mutants, which localized almost entirely
to perinuclear sites and showed minimal cell surface staining
above the background of untransduced cells. Of thembIFITM3 point
mutants, C72A had the most extensive perinuclear localization,
correlating with it showing the greatest loss of restriction (Fig 7). The
perinuclear expression of the P70W mutant was as prominent as
that seen for C105A and C71A, but for all three, a proportion of cells
expressed some IFITM3 at the cell surface and more widely within
the cells (Fig 8). As seen for mbIFITM3 P70W, the perinuclear IFITM3
co-localized with the cis Golgi marker Giantin (Fig 8B) and with the
trans Golgi network marker TGN46 (Fig S2A), and to a much lesser
extent with CD63-positive endolysosomes distributed throughout
the cells (Fig S2B).
In sum, our results show that S-palmitoylation is necessary for
viral restriction by microbat IFITM3 and that when S-palmitoylation
is reduced, either directly by targeted cysteine mutation or in-
directly via the P70W mutation, reduced restriction occurs con-
comitantly with IFITM3 localization to perinuclear, Golgi-associated
sites. Our data also indicate that for mbIFITM3 at least, defective
S-palmitoylation and altered intracellular trafficking underlie the
loss of viral restriction in the P70W mutant.
Discussion
Chiroptera are the natural reservoir hosts for numerous zoonotic
viruses, including IFITM3-sensitive viruses such as lyssaviruses and
IAV, which may have an extended evolutionary history in bats (61,
62). IFITM3 is a critical component of antiviral immunity in vivo in
humans and mice. However, its role in other species and its
mechanism(s) of restriction is not fully understood. Comparative
Figure 6. S-palmitoylation levels of cysteine mutants
of microbat IFITM3.
(A, B) A549 cells stably expressing the indicated HA-tagged
hu and mbIFITM3 proteins, or untransduced (untrans.) A549
cells, were lysed, subjected to acyl–biotin exchange, and
reacted with streptavidin, in triplicate for each IFITM3-
expressing cell line. SDS–PAGE (4μg total protein) andanti-HA
and anti-actin Western blotting was then performed.
(A) Quantification from triplicate acyl exchange experiments
each run on separate gels and blotted independently (mean
± SEM) **P < 0.01 relative to wt mbIFITM3 (t test). The
proportion of total IFITM3 protein palmitoylated is given by
densitometric quantitation (Image J) of (shifted HA signal)
/(total HA signal). (B) Representative Western blots for HA
(IFITM3) and actin (loading control) performed on the same
membrane. (C, D) A549 cells stably expressing the indicated
HA-tagged IFITM3 proteins, or untransduced (untrans.)
A549 cells, were incubated with the palmitate analogue
YnPalm(at 50μM)orwithDMSOonly (-YnPalm) for 16hbefore
lysis. Lysates were subjected to click chemistry using a
TAMRA capture reagent before proteins were separated by
SDS–PAGE (17 μg total protein loaded). Image J was used to
quantitate the intensity of TAMRA (direct detection with
Typhoon imager) and HA signal (from ECL) for each lane.
(C) TAMRA/HA ratios, normalized to wtmbIFITM3, for triplicate
YnPalm-treated lysates each subject to click chemistry, run
on separate SDS–PAGE gels and blotted independently
(mean ± SEM). *P < 0.05 relative to wt mbIFITM3 (t test). Inset
bar chart in (C) shows TAMRA/HA for mbIFITM3 proteins,
normalized to wt mbIFITM3, on an expanded scale. (D) A
representative gel. The top panel shows in-gel TAMRA
fluorescence, imaged directly with Typhoon imager. The
red asterisk shows the position of IFITM3 proteins running at
~15 kDa. Lower panels show corresponding Western blots for
the same gel for HA (IFITM3) and HSP90 (loading control).
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inter-species genomic analysis is a powerful tool to understand
host–pathogen interactions because genes and molecular de-
terminants that function in host defense carry evolutionary sig-
natures of adaptive evolution (63). Here, we included Chiroptera in
evolutionary analyses of mammalian IR-IFITMs and identified
strong adaptive evolution on the branch leading to bat IFITMs.
Functional studies showed that codon 70, which exhibits extensive
amino acid diversity among mammals, affects the antiviral activity
and S-palmitoylation of mbIFITM3 and, furthermore, that S-pal-
mitoylation is crucial for antiviral restriction by mbIFITM3 and has a
marked effect on its subcellular localization.
Analysis of lineage-specific selection pressures revealed a
strong signature of adaptive evolution on the branch leading to the
Chiropteran IFITM clade. This is not a general feature of Chiropteran
genes as, for example, the bat TLRs evolve under purifying selection
(64), and evidence for positive selection is only seen in 1% of
nuclear-encoded genes (65, 66). Importantly, the adaptive evolu-
tion we identified in bat IFITMs suggests that they serve an antiviral
role in vivo, and that at least some bat viruses must have exerted
major fitness costs on their hosts. Instances of virus-induced
disease in bats have been reported (67, 68, 69), and the high
viral richness per bat species (47) indicates that they harbor an
exceptionally large number of viruses. Notably, Chiroptera seem-
ingly harbor a greater variety of flaviviruses, bunyaviruses, and
rhabdoviruses than any other mammalian order (47), all of which are
RNA viruses restricted by IFITM proteins.
We previously showed that microbat IFITM3 is expressed con-
stitutively in primary cells, as reported for IFITM3 orthologues in
other species (33, 34, 41, 70, 71), andalso inducedbydsRNA, a pathogen-
associated molecular pattern (39). It has been suggested that basal
activation of the Chiropteran IFN system (72) limits viral replication and
enables disease tolerance (73), and our findings indicate that bat
IFITMs serve an adaptive function and may contribute to this mech-
anism. Interestingly, the evidence to date indicates that different
species’ IFITMs restrict viruses that are naturally hosted by these
species; for example, duck IFITM3 against IAV (40), nonhuman
primate IFITMs against SIV (43), and bat IFITM3 against lyssaviruses
(39). This suggests that evolution of viral antagonism of IFITMs, although
demonstrated for HIV-1 in vitro (74), may not occur readily in nature,
perhaps because IFITMs act so early in the viral replication cycle.
Codon 70 is especially diverse across the phylogeny of 31
mammalian IFITMs and lies within the highly conserved IFITM CD225
domain adjacent to known functionally important residues C71/C72.
We, therefore, chose to investigate the effects of amino acid di-
versity at this site and, to do so, substituted P70 in human IFITM3
with each of the other residues which occur naturally in functional
mammalian IFITMs (A, T, G, W, F, and V). None of these mutants
differed from wt in restricting three different viruses IAV, SFV, and
Figure 7. Antiviral restriction by cysteine mutants of
microbat IFITM3.
(A, B) A549 cells expressing the indicated IFITM3
proteins, or untransduced controls, were infected at an
MOI of 10 or 1 (alongside uninfected controls) with
either ZIKV for 28 h (A) or SFV_Zs-Green for 8 h (B).
Percentage infection was determined by high-
throughput confocal imaging using Hoechst-stained
nuclei to identify the total number of cells. For (A), the
infected cells were detected with an anti-flavivirus
primary antibody and AF 488–conjugated secondary
antibody (% infection = % AF 488 positive cells). For (B),
% infection = % Zs-Green positive cells. (C, D) For
lyssavirus entry assays, A549 cells expressing the
indicated IFITM3 proteins, or untransduced controls,
were transduced with lentiviral pseudotypes expressing
a firefly luciferase reporter and the G proteins from
either WCBV (C) or LBV (D) and luciferase activity
measured 48 h later (subtracting the luminescence
values of uninfected controls to give the net
luminescence values which were plotted on a log 10
scale). Each assay (A, B, C, and D) is a representative
experiment (n = 3) performed in triplicate (duplicate
for uninfected controls) with each bar showing the
mean ± SEM. At the bottom of the figure are Western
blots showing IFITM3 expression. IFITM3 proteins
were detected with an anti-HA antibody and
calreticulin was used as a loading control. (A, B, C, D) The
blot on the left corresponds to (A) and (B), whereas
the blot on the right corresponds to (C) and (D). The
lanes labelled mb WT-2 and mb P70W-2 in the left blot
refer to duplicate cell lines that were not used in the
infectivity assays. RLU, relative light units.
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ZIKV. An earlier report also showed that substituting P70 of human
IFITM3 with T, the residue present in human IFITM2, did not alter IAV
restriction or subcellular localization (22). Our study isolated the
effects of six different codon 70 residues within the background of
human IFITM3 but does not exclude the possibility that these
residues might have functional consequences in the context of
different IFITMs or against other viruses.
To investigate the function of codon 70 in Chiropteran IFITMs,
site-directedmutagenesis was performed on IFITM3 of themicrobat
M. myotis because this is the only Chiropteran IFITM reported to act
as a restriction factor (39). A P70W substitution was made because
tryptophan is common among the functional mammalian IFITMs in
our phylogenetic analysis and was inferred as a possible ancestral
codon (although the ancestral state reconstruction was ambiguous
at the tree root). Microbat P70W showed reduced restriction of IAV,
SFV, (Alphaviridae), ZIKV (Flaviviridae), and two lyssaviruses, con-
comitant with re-localization to perinuclear Golgi-associated sites and
reduced S-palmitoylation. As for mbIFITM3 P70W, S-palmitoylation–
defective cysteine mutants of microbat IFITM3 showed markedly
different localization from wt, with reduced expression at the cell
surface and retention at Golgi-associated sites. Based on the
evidence that restriction relies on the localization of IFITM proteins
at sites of viral entry (13, 14, 20), altered localization of the mbIFITM3
P70W and cysteine mbIFITM3 mutants likely explains their reduced
restriction of viruses that enter through endosomes. However,
whether deficient S-palmitoylation leads to altered localization or
whether altered localization prevents the proper enzymatic pro-
cesses of microbat IFITM3 S-palmitoylation remains to be studied.
The 23 different human ZDHHC palmitoyltransferases localize to
various different cellular sites, including the early secretory
pathway (ER and Golgi apparatus), plasma membrane, and endo-
cytic vesicles (75). McMichael et al have suggested that the location
at which IFITM3 is palmitoylated may influence its activity because
they found that ZDHHC20, which had the greatest effect on IFITM3
S-palmitoylation, also uniquely co-localized with IFITM3 at lyso-
somes (29).
Previous studies of equivalent S-palmitoylation–deficient cys-
teine mutants of human and murine IFITM3, including the triple
C71A-C72A-C105A mutant, showed no change in IFITM3 subcellular
localization (28, 30), whereas another study reported no change for
C71A and C105A but a more centralized intracellular distribution
for C72A than wt huIFITM3 (22). In contrast, all cysteine mutants of
mbIFITM3 relocalised to perinuclear Golgi-associated sites. Thus,
S-palmitoylation may positively regulate the antiviral activity of
human, murine, and microbat IFITM3 via different mechanisms,
including effects on protein–protein interactions, IFITM3 conformation,
Figure 8. Subcellular localization of cysteine mutants of microbat IFITM3.
Immunofluorescence of A549 cells stably expressing wt HA-tagged mbIFITM3, mbIFITM3 P70W, mbIFITM3 C71A, mbIFITM3 C72A, mbIFITM3 C105A, mbIFITM3 C71A-C72A, or
mbIFITM3 C71A-C72A-C105A (or untransduced A549 cells). (A) Cells were fixed and stained for HA with permeabilization (permeabilized) or without (intact). (B) Cells were
fixed, permeabilized, and stained for HA and the cis Golgi marker Giantin. Nuclei were labelled with Hoechst and images taken on a confocal microscope. Scale bars
represent 20 μm.
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membrane tethering/targeting, or the interplaywith other PTMs (26, 30).
As for human and murine IFITM3 (30), our data indicate that C72 is the
major site of S-palmitoylation inmicrobat IFITM3 with C72A showing the
most profound defect in restriction. Single mutation of each of C71, C72,
and C105 reproducibly impaired restriction by microbat IFITM3 in stable
A549 cells, indicating that each of these S-palmitoylation sites con-
tributes to antiviral function. In contrast, C105A but not C71A, reduced
restriction by murine IFITM3 (30), and neither C105A nor C71A signifi-
cantly impaired the antiviral activity of human IFITM3 (22, 30), including
when human IFITM3 mutants were stably expressed in A549s (22), as in
the current study.
These qualitative differences, either in the mechanisms or site-
specific effects of S-palmitoylation on human and microbat IFITM3,
may explain why the P70W mutation in human IFITM3 did not alter
its phenotype. Alternatively, quantitative differences may be re-
sponsible: huIFITM3 P70W was twofold less S-palmitoylated in our
metabolic labelling experiments than wt huIFITM3, but still more
S-palmitoylated than wt mbIFITM3. More S-palmitoylations on hu-
man compared with mbIFITM3 might enable wt huIFITM3 to tolerate
some reduced S-palmitoylation (e.g., with P70W), perhaps suggesting
a threshold level of S-palmitoylated IFITM3 is needed for restriction.
Codon 70 is located within a short unstructured portion of the
IMD, 69NPCC72 in human and microbat IFITM3, which separates two
alpha helices (9). The S-palmitoylated C71 and C72 residues are
highly conserved among IFITMs as well as the larger dispanin
protein superfamily (3). The other residue flanking codon 70, N69, is
also strongly evolutionarily conserved in IFITMs (Fig 2B) and
thought to be specifically required for proper termination of the
amphipathic helix (9). It is unlikely that the phenotype of our codon
70mutant relates to disruption of the amphipathic helix comprising
residues 59–68 because mutations in IFITM3 that destroy the
amphipathic helix, including complete deletion of the helix, are
S-palmitoylated at wild-type levels and localize normally (9). The
residue at codon 70 might affect the accessibility of C71/C72 for
acylation, or its cytoplasmic facing position could enable inter-
actions with ZDHHCs, with themselves, transmembrane proteins
with cytosolic DHHC-containing catalytic domains, or with protein
complexes such as those needed for ZDHHC-mediated S-palmi-
toylation of Ras (76). However, the recognition and specificity de-
terminants of ZDHHC protein substrates remains poorly understood
(77) and not yet studied in the case of IFITMs. Interestingly, codon 70
lies within a short stretch of amino acid residues which is only present
in the vertebrate DSPA proteins and no other dispanin superfamily
member (3), consistent with a role mapping to the antiviral function
that resides uniquely in some DSPA members.
Why such diversity has evolved at codon 70 among mammalian
IFITMs is unclear. It may reflect the diversity in IFITM-modifying ZDHHCs
among different species or differentially regulated S-palmitoylation
of different IR-IFITMs in the same species to ensure successfully
coordinated antiviral action in host cells. Alternatively, diversity at
codon 70may have evolved because of differences in the magnitude
or the type of virus-induced selection acting on different hosts.
Addressing these possibilities will require a range of different residues
to be systematically tested in their cognate IR-IFITMs and host cell
background against a range of viral targets, and for the pleotropic
cellular effects of IFITM expression to be similarly analyzed (25). Our
initial studies show that huIFITM3 or mbIFITM3 wt or codon 70
mutants do not affect proliferation of A549 cells (Fig S4). The liter-
ature on the viral and cellular roles of IFITMs has remained largely
discrete, although it is important to consider how these roles co-exist
and are regulated, particularly in light of the therapeutic potential of
IFITMs as antivirals. The recent report that IFITM expression inhibits
placental and fetal development by preventing trophoblast cell
fusion highlights a novel, noninfectious, selective pressure that may
oppose that of antiviral defense to shape IFITM evolution and reg-
ulation (78, 79). Such reproduction-based selection pressure likely
varies between mammals according to species’ fecundity, life history
traits, and placental physiology and, interestingly, may be another
driver of variation among mammalian IFITMs.
Materials and Methods
Identification of IFITM genes
IFITM genes from 31mammalian species were used for phylogenetic
analysis (Fig 1), including three species of megabat and 10 species
of microbat. IFITM sequences were derived either from our tran-
scriptional analyses or by tBLAST searches of NCBI nucleotide and
EST databases using human IFITM3 and IFITM1 as queries. For in-
clusion in phylogenetic analysis, genes identified via BLAST had to
have a CD225 domain, intact ORF of ~IFITM size, and two exons. IFITM
geneswere cloned fromprimary fibroblasts from themicrobat species
M.myotis, the FLN-R cell line derived frommicrobat E. serotinus (kindly
provided by Prof Martin Beer, Friedrich Loeffler Institute), and the pig
NPTr cell line, using RACE and RT-PCR methods as previously de-
scribed (39). The P. alecto IFITM3 gene sequence usedwas found using
proteomics informedby transcriptomics (53), which provided evidence
for transcript and protein expression in P. alecto cells. Uncharac-
terized IFITM sequences were named as “IFITM3-like” if their initiation
codons alignedwith known IFITM3 genes and “IFITM1-like” if their start
codon aligned with other IFITM1 genes. Table S1 shows IR-IFITM genes
with evidence for function (21, 39, 42, 46, 80) which were used to
analyse selection pressures.
Phylogenetic analysis
Multiple sequence alignment was performed using multiple runs of
the MAFFT procedure (81) at different stringencies as available in
the Geneious package (82). Sequence alignments were constructed
for (i) 148mammalian IFITM genes (alignment = 347 nt in length) and
(ii) 31 functional IFITM genes (alignment = 384 nt in length). In the
case of the 148 gene sequence alignment, all unaligned and am-
biguously aligned regions were removed using Gblocks (83, 84),
leaving 347 nt for analysis. Alignments are available from the au-
thors on request. Maximum likelihood phylogenies of data sets
were inferred using PhyML (85), employing the general time re-
versible model of nucleotide substitution and a gamma (Γ) model
of among-site rate variation with a proportion of invariant sites (I).
Analysis of clade-specific and codon-specific selection pressures
To assess selection pressures acting on IFITM genes (Table S1), we
computed the relative numbers of non-synonymous (dN) and
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synonymous (dS) nucleotide substitutions per site (i.e., the ratio dN/dS)
among the 31 functional IFITM genes using both the single-likelihood
ancestor counting and fast unconstrained Bayesian approximation
programs as implemented in the Datamonkey web server (http://
datamonkey.org), using default settings (86, 87). To assess the nature
of selection pressures on the branch leading to the Chiropteran IFITMs
we used the adaptive Branch-Site Random Effects Likelihood model
available on Datamonkey (56).
Cloning of microbat IFITM3 genes
RACE was conducted as described previously (39) on primary cells
from Pteropus hastatus and Carollia brevicauda. Based on RACE-
derived sequence, the following primers were designed to amplify
full IFITM3 genes by PCR: P. hastatus: 59-AGGAATCCGCTCTGTGTAGGG-
39 and 59-GGGAAGGGTGACAGCCTCAGG-39; C. brevicauda 59-
CATCTGCTCTGTTTAGGGACC-39 and 59-GCAGCCACCAGAAGCCTCCTA-39.
PCR performed on genomic DNA confirmed the presence of an intron.
Genes were assigned as IFITM3 based on having a long N-terminus
and double phenylalanine motif (F8/F9), as previously (39).
Cells and viruses
A549 cells (ATCC CCL-185) were cultured in Ham’s F-12 Nutrient
Mixture with GlutaMAX (F12; Gibco), supplemented with 10% (vol/
vol) FBS (Gibco). SFV_Zs-Green (a kind gift of Giuseppe Balistreri,
University of Helsinki, described in reference 88) was expanded and
titrated by plaque assay on BHK-21 cells (89). Zika virus (ZIKV) was
expanded and titrated by immunofocus assay on Vero cells. In-
fluenza A/WSN/33 virus (IAV) (H1N1) was grown in eggs and titrated
by plaque assay on MDCK cells.
IFITM3 mutagenesis
To generate mbIFITM3 P70W and huIFITM3 codon 70 mutants,
C-terminally HA-tagged wt IFITM3 genes in the lentiviral vector pHR-
SIN cGGW PGK puro were mutagenized using the QuikChange II XL
Site-Directed Mutagenesis Kit (Agilent) according to the manufac-
turer’s instructions using the following primers (all listed 59 to 39):
mbIFITM3 P70W: CGAAGCCCAGGCAGCACCAGTTGAAGAACAGGGTGTTG
and CAACACCCTGTTCTTCAACTGGTGCTGCCTGGGCTTCG; huIFITM3 P70A:
TTCAACACCCTGTTCATGAATGCCTGCTGCCTG and CAGGCAGCAGGCATT-
CATGAACAGGGTGTTGAA; huIFITM3 P70T: TGTTCAACACCCTGTTCATGAA-
TACCTGCTGCCTGG and CCAGGCAGCAGGTATTCATGAACAGGGTGTTGAACA;
huIFITM3 P70G: GTTCAACACCCTGTTCATGAATGGCTGCTGCCTGGG and
CCCAGGCAGCAGCCATTCATGAACAGGGTGTTGAAC; huIFITM3 P70W:
CCTGTTCAACACCCTGTTCATGAATTGGTGCTGCCTGGGCT and AGCCCAGG-
CAGCACCAATTCATGAACAGGGTGTTGAACAGG; huIFITM3 P70F:
CTGTTCAACACCCTGTTCATGAATTTCTGCTGCCTGGGC and GCCCAGG-
CAGCAGAAATTCATGAACAGGGTGTTGAACAG; huIFITM3 P70V:
GTTCAACACCCTGTTCATGAATGTCTGCTGCCTGGG and CCCAGGCAGCA-
GACATTCATGAACAGGGTGTTGAAC. To generate cysteine mutants,
C-terminally HA-tagged wt mbIFITM3 was subcloned from pHR-SIN
CSGW PGK Puro into pcDNA3.1 by BamHI/NotI digest. Cysteine-
to-alanine mutations were then introduced using the Q5 Site-
Directed Mutagenesis Kit (NEB) according to the manufacturer’s
instructions. Primers were as follows (all listed 59 to 39): For C71A –
CTTCAACCCCGCCTGCCTGGGCTTC and AACAGGGTGTTGAACAGG; for C72A –
CAACCCCTGCGCCCTGGGCTTCG and AAGAACAGGGTGTTGAACAG; for C105A
CACCGCCAAGGCCCTGAACATCTGGGC and CTGGCGTAGCTCTGGGCG; for
C71A-C72A – CTTCAACCCCGCCGCCCTGGGCTTCG and AACAGGGTGTTGAA-
CAGG. The C71A-C72A-C105A construct was cloned using the C105A
primers with the C71A-C72A construct as a template. Each of the five
mutant sequences were then subcloned back into pHR-SIN CSGW
PGK Puro by BamHI/NotI digest. All constructs were confirmed by
Sanger sequencing.
Generation of stable cell lines
A549 cell lines stably expressing variants of IFITM3were generated by
lentiviral transduction as previously described (39), but using the
lentiviral vector pHR-SIN CSGW PGK Puro expressing C-terminally
HA-tagged IFITM3 constructs. Transduction efficiency was checked
after 48 h by flow cytometric detection of HA. Transduced cells
were selected using 1.4 μg/ml puromycin (Thermo Fisher Sci-
entific) and the resultant polyclonal cell lines used for this
study.
Infectivity assays
ZIKV and SFV
Cells were infected in F12 with 2% FBS (infection media) and an-
alyzed after 8 h for SFV and 28 h for Zika virus. For flow cytometric
analysis, cells were trypsinized and fixed in 4% (wt/vol) formal-
dehyde (TAAB) for 20 min. For Zs-Green–expressing SFV infections,
fixed cells were washed in PBS, resuspended in FACS resuspension
buffer (1% [vol/vol] FBS, 2 mM EDTA in PBS), and stored at 4°C until
analyzed. For ZIKV infections, fixed cells were washed in PBS,
resuspended in FACS wash buffer (1% [vol/vol] FBS, 2 mM EDTA, 0.1%
[wt/vol] saponin in PBS) for 25 min at RT, and then stained with
mouse anti-flavivirus antibody (clone D1-4G2-4-15; Millipore) di-
luted 1:500 in FACS wash buffer for 90 min at RT. After washing twice
with FACS wash buffer, the cells were incubated with Alexa Fluor
(AF) 488–conjugated antimouse secondary antibody (diluted 1:800
in FACS wash buffer) for 1 h at RT. The cells were then washed twice
in FACS wash buffer and stored in FACS resuspension buffer at 4°C
until analyzed. For flow cytometry (LSR-II; BD Bioscience) cells were
gated on forward and side scatter and analyzed for FITC fluores-
cence. The data were processed using FlowJo vX.0.7 software (Tree
Star). For SFV and ZIKV infections analyzed by high-throughput
confocal imaging (90), the cells were plated for infection in 96-
well CellCarrier Ultra plates (Perkin Elmer). Fixation and staining
conditions were as described for flow cytometry, but with nuclei
stained with 5 μg/ml Hoechst-33258 (Sigma-Aldrich). Imaging was
performed on an Opera LX system (Perkin Elmer). For each well,
three images were acquired using a 4× objective (together ac-
counting for one-third of the total well area). Total cell numbers
and Zs-Green–infected cells or AF 488–positive cells were counted
using the PE Columbus software (Columbus 2.4.1.110801, PE, UK).
IAV
Analysis of influenza virus infectivity by flow cytometric detection of
nucleoprotein (NP) and analysis of multi-cycle influenza replication
was performed as described previously (39).
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Lyssavirus
Entry assays using lentiviral pseudotypes expressing a firefly lu-
ciferase reporter and the G proteins from either WCBV (AAR03484)
or LBV (LBV.NIG56-RV1; HM623779) were described previously (39).
Transductions were performed in triplicate on A549 cells in 96-well
plates, and 48 h later, the cells were lysed with 5× Passive Lysis
Buffer (Promega) and then added to luciferase substrate and lu-
ciferase activity measured on an Orion L Microplate Luminometer
(Berthold Detection Systems).
Immunofluorescence
Immunofluorescence on saponin-permeabilized cells was carried
out as described previously (5) except that cells were fixed in
methanol-free 4% (wt/vol) PFA (Alfa Aesar) in PBS. This same
procedure was followed for intact cells except that saponin was
omitted from the permeabilization buffer. For live cell staining, cells
cultured on coverslips were incubated in media containing primary
antibody for 1 h at 37°C with 5% CO2. The cells were washed twice in
the media and once in PBS to remove unbound antibody and then
fixed and either permeabilized or left intact and processed as
described above. Rat anti-HA primary antibody (clone 3F10, 1:100;
Roche) was detected with either goat antirat conjugated to AF 488
(1:500) or with donkey anti-rat AF 488 (1:500). Rabbit anti-giantin
primary antibody (discontinued, 1:1,000; Abcam) was detected with
goat antirabbit AF 647, sheep anti-TGN46 primary antibody (AHP500,
1:100; Bio-Rad) was detected with donkey antigoat AF 647 (1:500) and
mouse anti-CD63 primary antibody ((91); 1:10,000) was detected with
goat anti-mouse AF 647 (1:500).
Metabolic labeling and click chemistry analysis of
S-palmitoylated proteins
A549 cells (3 × 105 cells/well in a six-well plate) were incubated for
16 h with the alkyne palmitate (C16) analogue YnPalm (at 50 μM from
50 mM stock dissolved in DMSO) in F12 media with 3% FBS. A no-
YnPalm control was incubated in DMSO only in F12 media with 3%
FBS. The Cells were washed twice with PBS before lysis in 0.1 ml lysis
buffer (1% Triton X-100, 0.1% SDS, PBS, and complete EDTA-free
protease inhibitor [Roche]). Total protein concentration of lysates
was quantitated using the Pierce BCA assay (Cat. no. 23225) and then
adjusted to 1 mg/ml with lysis buffer. For each click reaction, 25 μg
total protein was incubated with click-mix comprising (at final
concentration) 100 μM capture reagent AzTB (azido-TAMRA-biotin),
1 mM CuSO4, 1 mM Tris(2-carboxyethyl)phosphine (TCEP), and 100
μM Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) for 60
min at room temperature. Proteins were then precipitated with two
volumes methanol, 0.5 volume chloroform, and one volume water.
The protein pellet was washed twice with methanol before boiling
in 1× non-reducing loading buffer for 5 min and loading onto a
4–15% TGX stain-free gel (4568085; Bio-Rad). After SDS–PAGE, the
gels were visualised using a Typhoon FLA 9500 imager (excitation
laser: 532 nm, emission filter: LPG [575–700 nm]; GE Healthcare) to
detect TAMRA (i.e., proteins labelled by the click reaction) and Cy5
(for MW markers). Proteins were then transferred onto PVDF for
Western blotting using anti-HA (ab18181, 1:1,000; Abcam) and
anti-HSP90 (sc-69703; Santa Cruz Biotechnology). Densitometric
quantification of TAMRA fluorescence (from Typhoon images) and
HA (following ECL) was performed on 16-bit images using Image J
1.47v.
Acyl–biotin exchange and gel shift analysis of S-palmitoylated
IFITM3
A549 cells grown in F12 media containing 10% FBS (7 × 105 cells/10 cm
dish) were washed twice in PBS and then lysed in 0.5 ml lysis buffer
(4% [wt/vol] SDS in triethanolamine [TEA] buffer [pH 7.3, 50 mM TEA,
and 150 mM NaCl] containing 5 mM EDTA and complete EDTA-free
protease inhibitor [Roche]). The total protein concentration of
lysates was quantitated using the Pierce BCA assay. 75 μg of total
protein in 100 μl of lysis buffer was subjected to acyl–biotin ex-
change using a modified protocol (30) (Fig S3A) in which, after
hydroxylamine (NH2OH) cleavage, alkylation was performed with
biotin–maleimide (B1267; Sigma-Aldrich) in TEA buffer at 1 mM
final concentration for 2 h at room temperature. After methanol–
chloroform–H2O precipitation (2:0.5:1), protein pellets were resus-
pended in 4× non-reducing SDS–PAGE buffer (8% SDS, 40% glycerol,
0.24M Tris HCl, pH 6.8, and 0.02%bromophenol blue), heated for 5min
at 95°C and allowed to cool for 30 min 6 μl (=10 μg) total protein was
then reacted with streptavidin (S4762; Sigma-Aldrich) in PBS (total
reaction volume 24 μl) for 5 min at RT. Assuming that IFITM3
comprised all of the total protein, streptavidin was used at a 0.5×
molar excess and titrations showed streptavidin was non-limiting
at this amount (Fig S3B). The samples were then run on 4–15% TGX
SDS–PAGE gels, with cooling packs to ensure heat generation did
not disrupt the biotin–streptavidin interaction. Proteins were
transferred to PVDF membranes, blocked in 5% BSA, and then
blotted using anti-HA (ab18181; Abcam, 1:1,000 in 0.5% BSA). After
ECL detection of HA, the membranes were washed in TBS-T,
blocked again in 5% BSA overnight, and re-blotted using anti-
actin (ab6276; Abcam, 1:1,000 in 0.5% BSA) to provide a loading
control. Image J was used to quantitate HA signal density from ECL
images using lane intensity plots. The proportion of total IFITM3
that was palmitoylated (and therefore shifted by streptavidin
binding to biotin-modified IFITM3-HA) was calculated as (HA
signal ≥ 75 kDa)/(total HA signal in lane).
Western blotting
Unless otherwise stated, the cells were lysed in Triton X-100 lysis
buffer (1% [vol/vol] Triton X-100, 25 mM Tris–HCl, pH 7.5, 100 mM
NaCl, 1 mM EDTA, and 1 mM EGTA containing complete EDTA-free
protease inhibitor). Protein concentrations were determined using
the Pierce BCA assay. Proteins were separated by 15% SDS–PAGE
and transferred to PVDF membranes. Membranes were blocked in
5% milk in PBST (PBS with 0.1% [vol/vol] Tween 20) and incubated
with antibodies diluted in PBST, either for 1 h at RT or overnight at
4°C. The following primary antibodies were used: rat anti-HA (clone
3F10, 1:1,000; Roche), mouse anti-HA (ab18181, 1:1,000; Abcam), rabbit
anti-calreticulin (PA3-900, 1:5,000; Thermo Fisher Scientific), and
anti-calnexin (CANX) (ab22595, 1:1,000; Abcam). For blots imaged
using an Odyssey system (Li-COR), goat antirat IRDye 800 secondary
(1:10,000) or goat antirabbit IRDye 680 (1:10,000) was used. For ECL
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detection, HRP-conjugated secondary antibodies and Luminata
HRP substrate (WBLUR0100; Millipore) were used.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900542.
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